Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CCT369260 is a degrader of Bcl-6.1 It induces degradation of Bcl-6 in SU-DHL-4, OCI-LY1, and Karpas-422 cells with half-maximal degradation concentration (DC50) values of 0.09, 0.049, and 0.062 µM, respectively. CCT369260 inhibits the growth of SU-DHL-4, OCI-LY1, and OCI-Ly3 cancer cells (GI50s = 0.092, 0.035, and 1.6 µM, respectively). It reduces intratumoral Bcl-6 levels in an OCI-LY1 lymphoma mouse xenograft model for up to ten hours after administration of a 15 mg/kg dose.
WARNING This product is not for human or veterinary use.
1. Achieving in vivo target depletion through the discovery and optimization of benzimidazolone BCL6 degraders. J. Med. Chem. 63(8), 4047-4068 (2020).